February 23: The Week in Cancer News
Melanoma drug becomes first cell therapy approved to treat a solid tumor, and a new method for treating mesothelioma extended patient survival in a recent trial.
Progress Against Cancer
Melanoma drug becomes first cell therapy approved to treat a solid tumor, and a new method for treating mesothelioma extended patient survival in a recent trial.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
The FDA has approved osimertinib plus chemotherapy for non-small cell lung cancer with EGFR mutations. The U.S. Food and Drug Administration (FDA) has approved osimertinib (Tagrisso) plus platinum-based chemotherapy for the treatment of patients...
Researchers explore a try-everything approach to precision medicine, and physical activity may help ease cancer pain.
The FDA has granted accelerated approval to lifileucel, a new type of cell therapy, for the treatment of melanoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to lifileucel (Amtagvi) for...
The FDA has granted full approval to tepotinib for some non-small cell lung cancers that harbor a certain mutation in the MET gene. The U.S. Food and Drug Administration (FDA) has approved tepotinib (Tepmetko)...
The FDA has approved irinotecan liposome plus chemotherapy for the first-line treatment of metastatic pancreatic cancer. The U.S. Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde), in combination with the chemotherapeutics oxaliplatin,...
Patients and doctors urge researchers to study lower doses for cancer treatments, and the FDA faces criticism for not issuing a formaldehyde ban in hair straighteners.
January’s selections include disparities in genetic testing, updates from a breast cancer clinical trial, and more.
The FDA has approved the FGFR inhibitor erdafitinib for certain patients with urothelial carcinoma The U.S. Food and Drug Administration (FDA) has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More